Guangdong Zhongsheng Pharmaceutical (002317.SZ): The first participant has been enrolled in the phase III clinical trial of the innovative drug Angla Diweiyekeli.

Guangdong Zhongsheng Pharmaceutical (002317.SZ) announced that recently, its holding subsidiary Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd. (hereinafter referred to as "Zhongsheng Ruichuang") has completed the first participant enrollment and dosing in the Phase III clinical trial of a new drug called Angladivir granules for the treatment of children aged 2-11 with uncomplicated influenza A. Angladivir tablets (trade name: Anruiwei) is the world's first innovative drug targeting the RNA polymerase PB2 subunit of influenza A virus, suitable for the treatment of uncomplicated influenza A in adults. It has the characteristics of rapid action, high efficacy, and low resistance, and was approved by the NMPA for marketing in May 2025. In order to meet the medication needs of adolescent influenza patients, the company has also conducted a Phase III clinical trial of Angladivir tablets for the treatment of adolescents aged 12-17 with uncomplicated influenza A, under the guidance of the PI at Ruijin Hospital, affiliated with Shanghai Jiao Tong University School of Medicine, with smooth enrollment of participants as of now. Angladivir granules is an innovative drug developed by the company for the treatment of influenza in children and patients with difficulty swallowing. The results of the Phase II clinical trial of Angladivir granules showed positive efficacy and good safety, with ideal results. Under the guidance of the PI at Beijing Children's Hospital, affiliated with Capital Medical University, the company recently completed the enrollment and dosing of the first participant in the Phase III clinical trial of Angladivir granules. The company will continue to advance both of these Phase III clinical trials with high quality, speed, and scientific rigor in accordance with relevant requirements.